Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gavi

- PMLiVE

Mesoblast expands compassionate use COVID-19 programme

Will now include children with multisystem inflammatory syndrome

- PMLiVE

Regeneron’s COVID-19 antibody cocktail enters phase 3 trial

Drug will be evaluated in preventative trial testing uninfected participants

- PMLiVE

Britain closes in on £500m COVID-19 vaccine deal with Sanofi/GSK

Alleged deal could include agreement for 60 million doses

- PMLiVE

WHO takes stock of global COVID-19 R&D progress

Researchers and developers meet virtually to discuss progress

- PMLiVE

NHS test and trace system ‘still not good enough’ says health leader

Test and trace system falls short in latest figures

- PMLiVE

Abivax doses first patient in phase 2b/3 COVID-19 clinical trial

Study will evaluate experimental anti-inflammatory drug

- PMLiVE

Pfizer jumps on early data from BioNTech-partnered COVID-19 vaccine study

Preliminary data demonstrates promising immunogenicity

- PMLiVE

Innovation in the time of coronavirus

The Distancer is a simple, handheld device that aims to help ensure the safety of key workers

- PMLiVE

New study identifies drugs that are safe to use in COVID-19 treatment

Researchers find no evidence for or against the use of drugs like ibuprofen

- PMLiVE

J&J says COVID-19 vaccine could be ready in early 2021

Also receives US federal backing to increase manufacturing for the shot

- PMLiVE

FDA grants emergency authorisation to chloroquine for COVID-19

Novartis and Bayer donate anti-malaria drugs to US stockpile

Sanofi reception

Sanofi doses first patient in global Kevzara COVID-19 trial

Sanofi is leading trials outside the US while Regeneron is leading US trials

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links